Skip to main content

Drug Interactions between gemfibrozil and resmetirom

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

gemfibrozil resmetirom

Applies to: gemfibrozil and resmetirom

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 2C8 may significantly increase the plasma concentrations of resmetirom, which is primarily metabolized by the isoenzyme. When clopidogrel, a moderate CYP450 2C8 inhibitor, was administered concomitantly with multiple doses of resmetirom (100 mg daily) to study subjects, resmetirom peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.3-fold and 1.7-fold, respectively. The risk of adverse effects such hepatotoxicity, gallbladder-related adverse reactions, diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, and dizziness may be increased. Clinical data exploring the use of potent CYP450 2C8 inhibitors (e.g. gemfibrozil) are not available.

MANAGEMENT: Concomitant use of resmetirom with potent CYP450 2C8 inhibitors should generally be avoided.

References (1)
  1. (2024) "Product Information. Rezdiffra (resmetirom)." Madrigal Pharmaceuticals, Inc.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer